In our previous study, we demonstrated that the lack of either AQP4 or TRPV4 slows down the development of cytotoxic edema in terminal ischemia and TRPV4 deletion attenuates the ECS volume decrease induced by OGD treatment in situ. The gene discussed is TRPV4; the disease is ischemia.